These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 20384328

  • 41. Ligand conformational and solvation/desolvation free energy in protein-ligand complex formation.
    Kolár M, Fanfrlík J, Hobza P.
    J Phys Chem B; 2011 Apr 28; 115(16):4718-24. PubMed ID: 21466174
    [Abstract] [Full Text] [Related]

  • 42. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
    de Mendoza C, Garrido C, Corral A, Zahonero N, Soriano V.
    AIDS; 2008 Jan 11; 22(2):311-3. PubMed ID: 18097236
    [Abstract] [Full Text] [Related]

  • 43. Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks.
    Wang D, Larder B.
    J Infect Dis; 2003 Sep 01; 188(5):653-60. PubMed ID: 12934180
    [Abstract] [Full Text] [Related]

  • 44. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H, King MS, King K, Molla A, Brun S, Kempf DJ.
    J Virol; 2005 Mar 01; 79(6):3329-38. PubMed ID: 15731227
    [Abstract] [Full Text] [Related]

  • 45. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
    Clemente JC, Robbins A, Graña P, Paleo MR, Correa JF, Villaverde MC, Sardina FJ, Govindasamy L, Agbandje-McKenna M, McKenna R, Dunn BM, Sussman F.
    J Med Chem; 2008 Feb 28; 51(4):852-60. PubMed ID: 18215016
    [Abstract] [Full Text] [Related]

  • 46. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
    Nijhuis M, Wensing AM, Bierman WF, de Jong D, Kagan R, Fun A, Jaspers CA, Schurink KA, van Agtmael MA, Boucher CA.
    J Infect Dis; 2009 Sep 01; 200(5):698-709. PubMed ID: 19627247
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
    Meher BR, Wang Y.
    J Phys Chem B; 2012 Feb 16; 116(6):1884-900. PubMed ID: 22239286
    [Abstract] [Full Text] [Related]

  • 50. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
    Perryman AL, Lin JH, Andrew McCammon J.
    Chem Biol Drug Des; 2006 May 16; 67(5):336-45. PubMed ID: 16784458
    [Abstract] [Full Text] [Related]

  • 51. How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding.
    Thorsteinsdottir HB, Schwede T, Zoete V, Meuwly M.
    Proteins; 2006 Nov 01; 65(2):407-23. PubMed ID: 16941468
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease.
    Li D, Liu MS, Ji B, Hwang KC, Huang Y.
    Chem Biol Drug Des; 2012 Sep 01; 80(3):440-54. PubMed ID: 22621379
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
    Dewdney TG, Wang Y, Liu Z, Sharma SK, Reiter SJ, Brunzelle JS, Kovari IA, Woster PM, Kovari LC.
    Bioorg Med Chem; 2013 Dec 01; 21(23):7430-4. PubMed ID: 24128815
    [Abstract] [Full Text] [Related]

  • 57. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
    Todd MJ, Luque I, Velázquez-Campoy A, Freire E.
    Biochemistry; 2000 Oct 03; 39(39):11876-83. PubMed ID: 11009599
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Explicit solvent dynamics and energetics of HIV-1 protease flap opening and closing.
    Sadiq SK, De Fabritiis G.
    Proteins; 2010 Nov 01; 78(14):2873-85. PubMed ID: 20715057
    [Abstract] [Full Text] [Related]

  • 60. Studies on adaptability of binding residues and flap region of TMC-114 resistance HIV-1 protease mutants.
    Purohit R, Rajendran V, Sethumadhavan R.
    J Biomol Struct Dyn; 2011 Aug 01; 29(1):137-52. PubMed ID: 21696230
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.